Elanco Animal Health (NYSE:ELAN) Stock Keeps Hold Rating at Jefferies Financial Group

Elanco Animal Health (NYSE:ELAN)‘s stock had its “hold” rating restated by equities researchers at Jefferies Financial Group in a research note issued on Tuesday, Marketbeat Ratings reports. They currently have a $24.00 price target on the stock, down from their previous price target of $31.00. Jefferies Financial Group’s target price suggests a potential upside of 8.54% from the stock’s previous close.

A number of other research analysts have also recently commented on ELAN. Morgan Stanley upped their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a report on Friday. They set a “buy” rating and a $32.00 target price for the company. Finally, KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average target price of $29.42.

Elanco Animal Health Trading Down 5.9%

Shares of ELAN traded down $1.38 during midday trading on Tuesday, reaching $22.11. The company had a trading volume of 879,071 shares, compared to its average volume of 5,584,529. Elanco Animal Health has a 1-year low of $19.40 and a 1-year high of $27.98. The stock has a market cap of $11.05 billion, a PE ratio of -54.33, a price-to-earnings-growth ratio of 1.68 and a beta of 1.70. The firm has a 50 day simple moving average of $23.25 and a 200-day simple moving average of $23.58. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts forecast that Elanco Animal Health will post 1.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Timothy J. Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider owned 138,911 shares in the company, valued at approximately $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lawrence Kurzius bought 40,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were purchased at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the transaction, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is owned by company insiders.

Institutional Trading of Elanco Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in ELAN. BlackRock Inc. acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $1,202,198,000. Primecap Management Co. CA acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $1,118,402,000. State Street Corp increased its position in Elanco Animal Health by 4.7% during the 2nd quarter. State Street Corp now owns 16,063,046 shares of the company’s stock worth $395,312,000 after purchasing an additional 726,567 shares during the period. The Manufacturers Life Insurance Company acquired a new position in Elanco Animal Health during the 2nd quarter worth approximately $205,636,000. Finally, Sei Investments Co. increased its position in Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after purchasing an additional 4,975,721 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.